- Home
- ACET vs FNGR Comparison
ACET vs FNGR Comparison
Compare ACET & FNGR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ACET
- FNGR
- Stock Information
- Founded
- ACET 1947
- FNGR 2016
- Country
- ACET United States
- FNGR Singapore
- Employees
- ACET N/A
- FNGR N/A
- Industry
- ACET Biotechnology: Pharmaceutical Preparations
- FNGR Computer Software: Prepackaged Software
- Sector
- ACET Health Care
- FNGR Technology
- Exchange
- ACET Nasdaq
- FNGR Nasdaq
- Market Cap
- ACET 83.2M
- FNGR 74.3M
- IPO Year
- ACET N/A
- FNGR N/A
- Fundamental
- Price
- ACET $0.98
- FNGR $1.37
- Analyst Decision
- ACET Buy
- FNGR
- Analyst Count
- ACET 5
- FNGR 0
- Target Price
- ACET $5.67
- FNGR N/A
- AVG Volume (30 Days)
- ACET 1.6M
- FNGR 255.3K
- Earning Date
- ACET 03-18-2025
- FNGR 01-14-2025
- Dividend Yield
- ACET N/A
- FNGR N/A
- EPS Growth
- ACET N/A
- FNGR N/A
- EPS
- ACET N/A
- FNGR N/A
- Revenue
- ACET N/A
- FNGR $33,570,107.00
- Revenue This Year
- ACET N/A
- FNGR $260.03
- Revenue Next Year
- ACET N/A
- FNGR N/A
- P/E Ratio
- ACET N/A
- FNGR N/A
- Revenue Growth
- ACET N/A
- FNGR N/A
- 52 Week Low
- ACET $0.81
- FNGR $1.03
- 52 Week High
- ACET $2.61
- FNGR $3.96
- Technical
- Relative Strength Index (RSI)
- ACET 57.01
- FNGR 57.63
- Support Level
- ACET $0.84
- FNGR $1.12
- Resistance Level
- ACET $1.04
- FNGR $1.38
- Average True Range (ATR)
- ACET 0.08
- FNGR 0.09
- MACD
- ACET 0.01
- FNGR 0.02
- Stochastic Oscillator
- ACET 68.65
- FNGR 92.59
About ACET Adicet Bio Inc.
Adicet Bio Inc is a clinical-stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for cancer and other diseases. Its lead product candidate, ADI-001, a first-in-class allogeneic gamma delta T cell therapy expressing a CAR targeting CD20, is being developed for the potential treatment of autoimmune diseases and relapsed or refractory aggressive B cell non-Hodgkin's lymphoma. Their pipeline also includes its lead preclinical candidate, ADI-270, an armored gamma delta CAR T cell product candidate targeting renal cell carcinoma, with potential for other CD70+ solid tumor and hematological malignancies indications.
About FNGR FingerMotion Inc.
FingerMotion Inc is engaged in the provision of mobile payment and recharge services in the Chinese market. The company business line includes Telecommunications Products and Services; Value Added Products and Services; Short Message Services (SMS) and Multimedia Messaging Services (MMS); a Rich Communication Services (RCS) platform; Big Data Insights; and a Video Games Division (inactive). It principally earns revenue by providing mobile payment and recharge services to customers of telecommunications companies in China.